TP53 and neoplasm: Similarly, we did not observe a correlation between clinical benefit and p53 positivity by IHC, suggesting that the cutoff for positive p53 staining used in this study (≥10% of tumor cells), may not predict clinical benefit and should be re-evaluated in future studies.